EXPRESS MAIL NO. EV333997180US		
DECLARATION OF KARL WEISGRABER UNDER 37 C.F.R. § 1.132	Attorney Docket Confirmation No.	UCAL-222 5282
	First Named Inventor	Karl H. Weisgraber
	Application Number	10/017,718
	Filing Date	December 14, 2001
	Group Art Unit	1632
	Examiner Name	T.N. Ton
Address to: Commissioner for Patents Alexandria, VA 22313-1450	Title	*Gene-targeted animal models of apolipoprotein E4 domain interaction and uses thereof*

Considered
9/28/04 TNT

Dear Sir:

1. I, Karl Weisgraber, declare and say I am a co-inventor of the claims of the above-identified patent application. I directed others and personally performed the research leading to the invention disclosed and claimed therein.

2. I have read the Office Action dated April 20, 2004, in this application and understand that the Examiner has rejected pending claims 1, 3, and 5 over Raffai et al. ((October 31, 2000) *Circulation* Vol. 102(18) Suppl. II-150 Abstract No. 729; "the Raffai Abstract").

3. The Raffai Abstract names Robert L. Raffai, Li-Ming Dong, Bryan Tow, Robert V. Farese, and Karl H. Weisgraber as authors. The instant patent application lists Karl H. Weisgraber, Robert V. Farese, Robert L. Raffai, Li-Ming Dong as inventors.

EXPRESS MAIL NO. EV333997180US		
DECLARATION OF KARL WEISGRABER UNDER 37 C.F.R. § 1.132	Attorney Docket Confirmation No.	UCAL-222 5282
	First Named Inventor	Karl H. Weisgraber
	Application Number	10/017,718
	Filing Date	December 14, 2001
	Group Art Unit	1632
Address to: Commissioner for Patents Alexandria, VA 22313-1450	Examiner Name	T.N. Ton
	Title	*Gene-targeted animal model of apolipoprotein E4 domain interaction and uses thereof*

Considered
9/28/04 TNT

Dear Sir:

1. I, Karl Weisgraber, declare and say I am a co-inventor of the claims of the above-identified patent application.

2. I have read the Office Action dated April 20, 2004 in this application and understand that the Examiner has rejected pending claims 1, 3, 5, 7, 14, 15, and 20-22 on the basis that, in the words of the April 24, 2004 Office Action, the instant specification fails to provide a correlation between the phenotype of the claimed transgenic mice and Alzheimer's Disease (AD).

3. The following paragraphs describe experiments conducted in my laboratory. The results of the experiments provide further evidence for the fact that a gene-targeted mouse that bears a Thr→Arg substitution at a position equivalent to Arg-61 in human apoE4 exhibits a phenomenon associated with AD, and therefore is suitable for use in identifying agents that reduce a phenomenon associated with AD.